CAS 1254036-66-2

GSK2292767

CAS : 1254036-66-2

GSK2292767 is a potent and selective PI3Kδ inhibitor.

Formule : C₂₄H₂₈N₆O₅S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 512.58

Ref: TM-T6850

rel-N-[5-[4-[5-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]methanesulfonamide

Produit contrôlé

CAS : 1254036-66-2

Applications rel-N-[5-[4-[5-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]methanesulfonamide is a selective PI3Kδ inhibitor for the treatment of respiratory disease (1,2).
References (1) Down, K., et al.: J Med Chem. 58, 7381 (2015)(2) Norman, P., Expert Opin Ther Pat. 22, 965 (2012)

Formule : C₂₄H₂₈N₆O₅S

Couleur et forme : Neat

Masse moléculaire : 512.58

Ref: TR-G797430

GSK2292767

CAS : 1254036-66-2

GSK2292767 is a small molecule that inhibits the protein kinase PI3Kδ. This inhibition blocks the activation of downstream proteins, including epidermal growth factor receptor (EGFR), which are involved in cell maturation and cancer. GSK2292767 has been shown to inhibit the growth of cancer cells in vitro and to reverse certain symptoms in animal models for autoimmune diseases. The drug has also been found to be effective against colorectal cancer and melanoma when used at an effective dose. GSK2292767 targets EGFR, which is important for cell maturation, proliferation, and apoptosis. It also inhibits the activity of PI3Kδ, which leads to the production of inflammatory cytokines by immune cells.
GSK2292767 is currently undergoing clinical trials as a treatment for certain types of cancer.

Formule : C₂₄H₂₈N₆O₅S

Degré de pureté : Min. 95%

Masse moléculaire : 512.58 g/mol

Ref: 3D-EAC03666